Remission

Adding anifrolumab to standard treatment for systemic lupus erythematosus led to faster achievement of low disease activity and remission, and more time spent in those states, vs. standard therapy alone, according to data.

SAN DIEGO — Remission persisted through 104 weeks for most patients with eosinophilic granulomatosis with polyangiitis who used benralizumab, according to a poster presented here.

Of four treatment response measures recorded at 6 months of mepolizumab treatment, an Asthma Control Questionnaire score was deemed “best predictor” of 12-month remission in patients with severe eosinophilic asthma, according to study data.

Although sustained remission free of disease-modifying antirheumatic drugs “does not seem attainable” for patients with rheumatoid arthritis requiring biological DMARDs, it is possible for those who do not require them, according to data.

Targeted therapies for active inflammatory arthritis should be started “without delay” for patients with cancer in remission, according to new EULAR points to consider published in Annals of the Rheumatic Diseases.

WASHINGTON — CD19 chimeric antigen receptor T-cell therapy led to remission, or ceased disease progression, over a period of up to 15 months in 35 patients with lupus, myositis and systemic sclerosis, according to data.

BOSTON — Targeting asthma remission as the next goal in asthma therapy should be prioritized, according to a presentation at the CHEST Annual Meeting.

Patients with severe Behçet’s syndrome who received infliximab demonstrated better odds of achieving complete response at 22 weeks compared with those who used cyclophosphamide, according to head-to-head data published in NEJM Evidence.

Long-term filgotinib induced and maintained symptomatic remission and improved health-related quality of life in ulcerative colitis, with no new safety signals reported, according to interim analysis of the SELECTION extension study.